ISRAEL and TORONTO, May 03, 2018 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (TSX VENTURE:VXL), a cancer research biotechnology company focused on innovative immunotherapy treatments, has been granted a patent from the Indian Patent Office for its ImMucinTM cancer immunotherapy. The granted Indian patent has been assigned as Patent No. 294701 entitled “Antigen Specific Multi Epitope Vaccines”.

 Vaxil’s lead product, ImMucinTM, has already completed a Phase-I/II in 15 cancer patients in Israel. ImMucinTM is an immunotherapy treatment intended to train and harness cancer patients’ immune systems, particularly T-cells and antibodies, to attack cancer cells. ImMucin has also been granted Orphan Drug Designation from both the FDA and EMA for the treatment of multiple myeloma, although Vaxil hopes to test its applicability on other MUC1 cancer types as well.

“We are pleased to have been granted broad patent coverage for our lead cancer immunotherapy treatment in a variety of key jurisdictions around the globe. ImMucinTM is now protected in the United States of America, the European Union, Canada, Australia, Israel, and India,” noted Vaxil CEO Mr. Isaac Maresky. “Vaxil has advanced from a single Israeli patent to the present nine patents - including three US patents on all Vaxil product candidates - most of which have been obtained in just the past couple years.”

Vaxil’s treatment exposes the signal peptide domain, essentially a specific portion of a prominent cancer marker called MUC1 which is present in approximately 90% of cancer types. Vaxil believes that its specific peptide may have potential to offer significant advantages as an immunotherapy treatment.

The granted patent includes claims covering the ImMucinTM 21-mer peptide nucleotide sequence and expression vector encoding the ImMucinTM peptide, as well as vaccines and pharmaceutical composition comprising the vaccine being the ImMucinTM peptide.

CORPORATE UPDATE
As mentioned in its most recent announcement: “Vaxil remains focused on advancing the drug manufacturing processes for its lead cancer immunotherapy product known as ImMucinTM. While manufacturing of the drug substance has begun, the Company is in discussions with relevant experts pertaining to Chemistry, Manufacturing and Controls (CMC). The Company is working on identifying an optimal CMC process for production of its drug which will in turn allow efficient production via a Current Good Manufacturing Practices (CGMP) approved facility. The goal of such an endeavor is to enhance Vaxil’s ability to more readily produce larger quantities of high quality product, which would enable the Company to embark upon additional clinical trials.  CMC is an important bridge between clinical pilot batches of therapeutic drugs to more commercial-scale batches. The Company hopes to be in a position to report more on the manufacturing process and its CMC direction in the near future.” This process remains underway with relevant testing in process.

ABOUT VAXIL
Vaxil is an Israeli immunotherapy biotech focused on its novel approach to targeting prominent cancer markers utilizing its platform algorithm known as VaxHitTM. Its lead product Immucin™ is a MUC1 signal peptide derived product, wholly owned by Vaxil and protected by a series of patents in several major territories around the globe, believed to act as a true neoantigen. Vaxil has also developed an antibody platform, SPmAbTM and a Tuberculosis vaccine called MTBuVaxTM with R&D underway in Israel.

CORPORATE WEBSITE
Information about the Company’s pipeline, including published medical journal articles available for direct download, is available at www.vxlbio.com.

Disclaimer: The TSX Venture Exchange Inc. has in no way passed upon the merits of the Company has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including the availability of funds, the results of financing efforts, the results of exploration activities -- that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the United States or elsewhere. These securities have not been, and will not be, registered in the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States or to U.S. persons unless registered or exempt therefrom.

CONTACT INFORMATION
For further information please visit www.vxlbio.com or contact:
Isaac Maresky, CEO -- Email contact

A photo accompanying this announcement is available at http://resource.globenewswire.com/Resource/Download/f1471e14-03e8-483c-be2c-d27af621206b